SCHEDULE: Ong Yee Lung Discloses 9.8% Stake in Cyclacel Pharma

Ong Yee Lung has reported a 9.8% beneficial ownership stake in Cyclacel Pharmaceuticals, Inc., holding 218,000 shares of common stock.

Summary

• Ong Yee Lung has filed a Schedule 13G, disclosing beneficial ownership of 218,000 shares of Cyclacel Pharmaceuticals, Inc. common stock.
• This ownership represents 9.8% of the company's outstanding common stock.
• The shares are held with sole voting power and sole dispositive power.
• The event requiring this filing occurred on July 28, 2025.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Positives

• A significant individual stake of 9.8% in Cyclacel Pharmaceuticals, Inc. by Ong Yee Lung indicates a notable investment and potential confidence in the company.

Risks

• The reporting person certified that the securities were not acquired or held for the purpose or effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Disclosure of a significant individual shareholder.

Key Dates

Keywords

Cyclacel Pharmaceuticals, Ong Yee Lung, Schedule 13G, Beneficial Ownership, Common Stock, Pharmaceutical, Investment, Stake, SEC Filing